Welcome to our dedicated page for Bioadaptives SEC filings (Ticker: BDPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bioadaptives Inc (BDPT) files periodic reports and disclosures with the Securities and Exchange Commission, providing detailed information about the company's financial condition, business operations, risk factors, and corporate governance. As a publicly traded company on the OTC markets, Bioadaptives maintains regulatory reporting obligations that generate documents investors can examine to understand the company's business model, financial trajectory, and operational challenges.
For micro-cap nutraceutical companies like Bioadaptives, SEC filings reveal critical information often not available through press releases or marketing materials. The company's 10-K annual reports detail revenue sources, cost structures, cash positions, and the viability of the business model, while 10-Q quarterly reports track financial trends across reporting periods. Given the company's limited revenue and development-stage characteristics, these financial disclosures provide essential context about burn rates, capital requirements, and going concern considerations that significantly impact investment risk.
Form 4 filings documenting insider transactions offer perspective on how company officers, directors, and significant shareholders view the business. Patterns of insider buying or selling, particularly among executives with direct knowledge of operations, can signal confidence or concerns not yet reflected in public communications. For small-cap companies with limited analyst coverage, insider transaction patterns sometimes provide early indicators of business developments.
8-K current reports disclose material events including executive changes, financing arrangements, significant contracts, and corporate structure modifications. For Bioadaptives, 8-K filings may document product licensing agreements, subsidiary formations or modifications, capital raises, or changes in business strategy. These filings often provide the first public disclosure of developments that will shape the company's future direction. Our platform provides AI-powered summaries of complex filings, helping you quickly identify key disclosures without reading hundreds of pages of technical documentation.
BioAdaptives, Inc. director reports stock-based board compensation. A company director received 2,286 shares of BioAdaptives Series D Convertible Preferred Stock on 01/01/2026 as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share has a stated par value of $0.0001 and is convertible into 100 shares of common stock, for an underlying 228,600 common shares, subject to a 4.9% beneficial ownership limitation.
No Series D shares may be converted until six months after issuance, except that conversion occurs immediately upon liquidation. Each preferred share carries 100 votes in stockholder matters, and the conversion right does not expire. Following this transaction, the reporting person held 57,217 derivative securities in the form of Series D Convertible Preferred Stock, owned directly.
Bioadaptives, Inc.12/01/2025, the director received 2,025 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share is convertible into 100 shares of common stock, for a total of 202,500 underlying common shares, but conversions are subject to a 4.9% beneficial ownership limitation.
The preferred shares generally cannot be converted until six months after issuance, except that conversion occurs immediately in a liquidation. Each preferred share carries 100 votes on stockholder matters and the conversion right does not expire. After this transaction, the reporting person beneficially owned 54,931 derivative securities, held directly.
BioAdaptives, Inc. (BDPT) reported Q3 2025 results, showing a wider net loss and continued liquidity pressure. Net loss was $379,502 for the quarter, compared with $37,649 a year ago, as operating expenses and derivative fair value changes weighed on results. Revenue reached $4,632 in Q3 as limited PawPa Regen sales began.
For the nine months, net loss totaled $734,552 on revenue of $7,851. Cash was $59,273 at September 30, 2025, with current assets of $108,860 versus current liabilities of $1,589,570, resulting in a working capital deficiency of $1,480,710. The company reported a stockholders’ deficit of $1,465,210, including derivative liabilities of $967,406 and convertible notes of $359,300.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and noted material weaknesses in internal controls. Financing activities included $300,000 of cash proceeds from Series D preferred stock and debt-to-equity conversions. Common shares outstanding were 12,008,659 as of October 17, 2025.
BioAdaptives (BDPT) director filed a Form 4 reporting the acquisition of 1,382 shares of Series D Convertible Preferred Stock on 11/01/2025, issued as compensation for board services. The filing lists a $0 price for the derivative award.
Each Series D share is convertible into common stock at a 100:1 ratio, corresponding to 138,200 underlying common shares, subject to a 4.9% beneficial ownership limitation. The Series D shares become convertible six months after issuance (stated as 05/01/2026), with conversion occurring immediately in a liquidation scenario. Each Series D share carries 100 votes on matters of the issuer, and the right to convert does not expire.
Mark P. Frissora, a director of BioAdaptives, Inc. (BDPT), received compensation in the form of Series D Convertible Preferred Stock on
FAQ
What is the current stock price of Bioadaptives (BDPT)?
What is the market cap of Bioadaptives (BDPT)?
